- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00028028
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized, Phase II ECOG Trial of Two Dose Levels of CCI-779 in Patients With Extensive-Stage Small Cell Lung Cancer Who Have Responding or Stable Disease After Induction Chemotherapy
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVES:
I. To study the progression-free survival in patients who receive a lower or a higher dose of CCI-779, a cytostatic agent following cytoreductive chemotherapy in extensive SCLC.
II. To determine the toxicity of two treatment regimens involving a lower or a higher dose of CCI-779.
SECONDARY OBJECTIVES:
I. To quantify the effects of CCI-779 treatment on p70S6 phosphorylation in peripheral blood mononuclear cells of patients with small cell lung cancer who are treated with CCI-779.
II. To measure the effects on mTOR activation and signaling of plasma from patients treated with CCI-779.
III. To determine the relationship between CCI-779 dose and its pharmacodynamic parameters.
IV. To correlate the inhibition of p70S6 with indices of patient outcome.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to brain metastases (yes vs no), prior induction chemotherapy regimen (platinum and etoposide vs platinum and irinotecan), and response to prior induction chemotherapy (complete or partial response vs stable disease). Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive low-dose CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive high-dose CCI-779 as in arm I.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Eastern Cooperative Oncology Group
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Patients must have histologically-confirmed small cell carcinoma of the lung or unequivocally positive cytological evidence (sputum [at least 2] or aspirate biopsy), with extensive disease (disease beyond the hemithorax and adjacent nodes, supraclavicular node involvement or pleural effusion with positive cytology), who have required induction chemotherapy, who have responding or stable disease, and who meet the following criteria:
- Induction chemotherapy including platinum (cisplatin or carboplatin) plus either etoposide (VP-16) or irinotecan (CPT-11)
- A minimum of 3 and a maximum of 6 cycles of induction chemotherapy have been administered
- Recovered from all toxicity related to prior chemotherapy (except alopecia and/or neuropathy)
- No less than 4 and no more than 8 weeks have elapsed between the last treatment of induction chemotherapy and randomization
- No more than 32 weeks have elapsed between the first dose of induction chemotherapy and date of randomization
- The patient has responding or stable disease using RECIST criteria since the initiation of systemic chemotherapy (i.e., patients who have exhibited disease progression are NOT ELIGIBLE)
- Patients must be disease-free for >= 5 years if they have had a prior second malignancy other than treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
- Baseline measurements/evaluations of disease must be obtained =< 4 weeks prior to randomization
- WBC >= 4000/mm³ or
- ANC >= 1500/mm³
- Platelet count >= 100,000/mm³
- Total bilirubin =< 1.5 mg/dl
- Creatinine =< 1.5 mg/dl
- Patient's cholesterol level must be < 350mg/dl; (note; if non-fasting levels are high repeat in a fasting state)
- Patient's triglycerides must be < 400mg/dl; (note; if non-fasting levels are high repeat in a fasting state)
- ECOG performance status 0, 1, or 2
- Prior radiation to any symptomatic site is permitted so long as the site(s) of measurable disease are NOT irradiated, and radiation is completed at least 4 weeks before randomization
- Patients must not have had prior treatment with biological response modifiers
- Patients with brain metastases are eligible provided they have received treatment, are asymptomatic and are no longer taking corticosteroids; patients who develop brain metastases after completion of induction chemotherapy are ineligible
- Patients must not be on anticonvulsant therapy
- Patients must not have limited disease
- Patients must not become pregnant and must practice adequate contraception; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and continue approximately 12 weeks after the study is completed; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; female patients who are breastfeeding are also excluded from this study
- Patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to CCI-779, or to any of the components of the CCI-779 formulation; patients must also not be allergic to or for medical reasons are unable to receive antihistamines
- Patients must not be immunocompromised, have an active infection or serious intercurrent infection, or have received known immunosuppressive therapies within 3 weeks randomization
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Arm I
Patients receive low-dose CCI-779 IV over 30 minutes once weekly.
Treatment continues in the absence of disease progression or unacceptable toxicity.
|
Estudios correlativos
Estudios correlativos
Otros nombres:
Dado IV
Otros nombres:
|
Experimental: Arm II
Patients receive high-dose CCI-779 as in arm I.
|
Estudios correlativos
Estudios correlativos
Otros nombres:
Dado IV
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression-free survival (PFS)
Periodo de tiempo: Time to death or relapse, assessed up to 6 years
|
A log-rank test will compare the PFS curves of both arms.
|
Time to death or relapse, assessed up to 6 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Toxicity rate graded according to NCI CTC version 2.0
Periodo de tiempo: Up to 6 years
|
The difference in the true toxicity rates of the two arms will be detected using Fisher's exact test.
|
Up to 6 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Kishan Pandya, Eastern Cooperative Oncology Group
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células pequeñas
- Efectos fisiológicos de las drogas
- Agentes antiinfecciosos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes antibacterianos
- Antibióticos, Antineoplásicos
- Agentes antifúngicos
- Sirolimus
Otros números de identificación del estudio
- NCI-2012-03146
- U10CA021115 (Subvención/contrato del NIH de EE. UU.)
- E1500
- CDR0000069118 (Identificador de registro: PDQ (Physician Data Query))
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre análisis de biomarcadores de laboratorio
-
ORIOL BESTARDTerminadoTrasplante de riñón | Infección por CMVEspaña, Bélgica
-
Vanderbilt University Medical Center4DMedicalTerminado
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Aún no reclutandoInfecciones por VIH | Hepatitis B
-
Johns Hopkins UniversityReclutamiento
-
University of MiamiActivo, no reclutando
-
Hvidovre University HospitalElsassFondenTerminadoAcidosis metabólica del recién nacidoDinamarca
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... y otros colaboradoresTerminadoEnfermedades cardiovasculares | Deficiencia de vitamina D | Condiciones relacionadas con la menopausiaBrasil